Post

Vertex says Casgevy benefit extends to nearly five years in sickle cell disease

Vertex Pharmaceuticals has reported long-term data for its gene therapy Casgevy (exa-cel) in patients with sickle cell disease or transfusion-dependent …

First patients enrolled on Veris’ CCP pilot programme 

The first patients have been enrolled on a pilot programme launched by Pavmed’s digital health subsidiary Veris Health and the …

Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial

Aldeyra Therapeutics has concluded the subject enrolment in its Phase III clinical trial of topical ocular 0.25% reproxalap, a new …

CyanVac secures funding for Phase IIb intranasal Covid-19 vaccine trial

CyanVac has received US federal funding through the Project NextGen initiative to conduct a Phase IIb comparative clinical trial of …

WHO publishes new mpox prevention and management framework

Mpox, caused by the monkeypox virus (MPVX), continues to affect people around the world. The disease causes a painful rash, …